lobbying_activities: 1452740

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1452740	71f42eef-3ba5-418c-9121-6e02f5cf824e	Q3	THE DUBERSTEIN GROUP INC.	12675	PFIZER INC.	2013	third_quarter	PHA	Pharmaceutical issues, including track and trace legislation - HR 1919, Safeguarding America's Pharmaceuticals Act of 2013; S 957, Drug Supply Chain Security Act; HR 3204, Drug Quality and Security Act. Specialty drug tiers - HR 460, Patients' Access to Treatments Act of 2013.Regulation of compounded drugs - HR 3019, S.A.F.E. Compounded Drugs Act of 2013; S 959, Pharmaceutical Quality, Security, and Accountability Act; HR 3204, Drug Quality and Security Act.	HOUSE OF REPRESENTATIVES,SENATE	100000		0	0	2013-10-18T14:44:23.327000-04:00